# Combination Study for High Risk Multiple Myeloma Patients

> **NCT03104270** · PHASE2 · TERMINATED · sponsor: **Oncotherapeutics** · enrollment: 13 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Elotuzumab
- **DRUG:** Pomalidomide
- **DRUG:** Carfilzomib
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT03104270
- **Lead sponsor:** Oncotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-03-13
- **Primary completion:** 2019-10-25
- **Final completion:** 2020-01-23
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** The study was terminated early by Funding Sponsor due to low enrollment.
- **Last updated:** 2022-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03104270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03104270, "Combination Study for High Risk Multiple Myeloma Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03104270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*